| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Adam Kaminski, Hua Xie, Brylee Hawkins, Chandan J Vaidy. Change in Striatal Functional Connectivity Networks Across Two Years Due to Stimulant Exposure in Childhood ADHD: Results from the ABCD Sample. medRxiv : the preprint server for health sciences. 2024-04-02. PMID:38562872. |
widely prescribed as the first choice of treatment for attention-deficit/hyperactivity disorder (adhd), stimulants (methylphenidate and amphetamines) have been studied for their long-term effects on the brain in prospective designs that carefully control dosage and adherence. |
2024-04-02 |
2024-04-04 |
Not clear |
| Raghu Gandhi, Aimee Murra. Lisdexamfetamine-Induced Psychosis in a Patient With a Neurodevelopmental Disorder. Cureus. vol 16. issue 1. 2024-03-04. PMID:38435908. |
the authors recommend considering the methylphenidate class of stimulants as a first-line treatment for adhd in individuals with asd, citing better tolerability compared to amphetamines. |
2024-03-04 |
2024-03-06 |
Not clear |
| Luis C Farhat, José M Flores, Victor J Avila-Quintero, Guilherme V Polanczyk, Andrea Cipriani, Toshi A Furukawa, Michael H Bloch, Samuele Cortes. Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA psychiatry. 2023-10-27. PMID:37878348. |
stimulants (methylphenidate and amphetamines) are often prescribed at unlicensed doses for adults with attention-deficit/hyperactivity disorder (adhd). |
2023-10-27 |
2023-11-08 |
Not clear |
| Derek J Baughman, Crista M Watson, Jonathan W Beich, May N Joresa Herboso, Liana K Cuttie, Ari-Beth C Marlyn. Recommendation for Long-term Management of Adult Attention-Deficit/Hyperactivity Disorder in Military Populations, Veterans, and Dependents: A Narrative Review. Military medicine. 2023-10-25. PMID:37878798. |
despite the low prevalence of new-onset adhd in adults globally, the rate of stimulant (i.e., amphetamines) prescription is increasing. |
2023-10-25 |
2023-11-08 |
Not clear |
| Felix P Mayer, Adele Stewart, Durairaj Ragu Varman, Amy E Moritz, James D Foster, Anthony W Owens, Lorena B Areal, Raajaram Gowrishankar, Michelle Velez, Kyria Wickham, Hannah Phelps, Rania Katamish, Maximilian Rabil, Lankupalle D Jayanthi, Roxanne A Vaughan, Lynette C Daws, Randy D Blakely, Sammanda Ramamoorth. Kappa Opioid Receptor Antagonism Rescues Genetic Perturbation of Dopamine Homeostasis: Molecular, Physiological and Behavioral Consequences. bioRxiv : the preprint server for biology. 2023-05-19. PMID:37205452. |
we established that the human da transporter (dat) coding variant (dat val559), identified in individuals with adhd, asd, or bpd, exhibits anomalous da efflux (ade) that is blocked by therapeutic amphetamines and methylphenidate. |
2023-05-19 |
2023-08-14 |
mouse |
| Christopher L Robinson, Katelyn Parker, Saurabh Kataria, Evan Downs, Rajesh Supra, Alan D Kaye, Omar Viswanath, Ivan Urit. Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder. Health psychology research. vol 10. issue 3. 2022-09-28. PMID:36168642. |
stimulants, such as methylphenidate and amphetamines, are the mainstay of treatment for adhd. |
2022-09-28 |
2023-08-14 |
Not clear |
| Andrew J Cutler, Katsumi Suzuki, Brittney Starling, Kanan Balakrishnan, Marina Komaroff, Mariacristina Castell. d-Amphetamine Transdermal System in Treatment of Children and Adolescents with ADHD: Secondary Endpoint Results from a Phase 2 Trial. CNS spectrums. vol 27. issue 2. 2022-04-28. PMID:35477594. |
amphetamines are a first-line treatment for adhd. |
2022-04-28 |
2023-08-13 |
Not clear |
| Luis C Farhat, José M Flores, Emily Behling, Victor J Avila-Quintero, Adam Lombroso, Samuele Cortese, Guilherme V Polanczyk, Michael H Bloc. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molecular psychiatry. 2022-01-14. PMID:35027679. |
clinical guidelines currently recommend practitioners titrate stimulant medications, i.e., methylphenidate (mph) and amphetamines (amp), to the dose that maximizes symptom control without eliciting intolerable adverse events (aes) when treating attention-deficit/hyperactivity disorder (adhd) in school-aged children/adolescents. |
2022-01-14 |
2023-08-13 |
Not clear |
| James R Latronica, Taylor J Clegg, Wen-Jan Tuan, Curtis Bon. Are Amphetamines Associated with Adverse Cardiovascular Events Among Elderly Individuals? Journal of the American Board of Family Medicine : JABFM. vol 34. issue 6. 2021-12-09. PMID:34772763. |
prescription amphetamines are the most common pharmacological treatment for attention deficit hyperactivity disorder (adhd) and use among older age groups is increasing. |
2021-12-09 |
2023-08-13 |
Not clear |
| Samuele Cortese, Jeffrey H Newcorn, David Coghil. A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). CNS drugs. vol 35. issue 10. 2021-11-09. PMID:34403134. |
stimulants (methylphenidate or amphetamines) are the recommended first-line option for the pharmacological treatment of individuals with attention deficit hyperactivity disorder (adhd). |
2021-11-09 |
2023-08-13 |
Not clear |
| Joan D Garey, Shari I Lusskin, Anthony R Sciall. Teratogen update: Amphetamines. Birth defects research. vol 112. issue 15. 2021-08-18. PMID:32755038. |
controlled studies of amphetamine use for the treatment of adhd and other indications did not suggest that amphetamines are likely to cause structural malformations, although there are three studies associating medication for adhd or methamphetamine abuse with gastroschisis. |
2021-08-18 |
2023-08-13 |
Not clear |
| Derek Blevins, C Jean Choi, Martina Pavlicova, Diana Martinez, John J Mariani, John Grabowski, Frances R Levi. Impulsiveness as a moderator of amphetamine treatment response for cocaine use disorder among ADHD patients. Drug and alcohol dependence. vol 213. 2021-08-02. PMID:32485656. |
amphetamines are a first-line treatment for adhd and have shown promise for the treatment of cocaine use disorder (cud), both alone and with comorbid adhd. |
2021-08-02 |
2023-08-13 |
Not clear |
| Funda Inan, Tibor M Brunt, Ramon R Contrucci, Laura Hondebrink, Eric J F Fransse. Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. Therapeutic drug monitoring. vol 42. issue 2. 2021-05-05. PMID:32022784. |
various phenethylamines and nps are also highly used in populations with mental disorders, depression, or attention deficit hyperactivity disorder (adhd). |
2021-05-05 |
2023-08-13 |
Not clear |
| Funda Inan, Tibor M Brunt, Ramon R Contrucci, Laura Hondebrink, Eric J F Fransse. Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. Therapeutic drug monitoring. vol 42. issue 2. 2021-05-05. PMID:32022784. |
considering these specific populations and their frequent concurrent use of drugs, such as antidepressants, adhd medication, and antiretrovirals, reports on potential interactions between these drugs, and phenethylamines 4-fa and 2c-b, were reviewed. |
2021-05-05 |
2023-08-13 |
Not clear |
| Stephen V Faraon. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience and biobehavioral reviews. vol 87. 2019-02-18. PMID:29428394. |
psychostimulants, including amphetamines and methylphenidate, are first-line pharmacotherapies for individuals with attention-deficit/hyperactivity disorder (adhd). |
2019-02-18 |
2023-08-13 |
Not clear |
| Xavier Castells, Lídia Blanco-Silvente, Ruth Cunil. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. The Cochrane database of systematic reviews. vol 8. 2019-01-16. PMID:30091808. |
amphetamines for attention deficit hyperactivity disorder (adhd) in adults. |
2019-01-16 |
2023-08-13 |
Not clear |
| Xavier Castells, Lídia Blanco-Silvente, Ruth Cunil. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. The Cochrane database of systematic reviews. vol 8. 2019-01-16. PMID:30091808. |
amphetamines are used to treat adults with adhd, but uncertainties about their efficacy and safety remain. |
2019-01-16 |
2023-08-13 |
Not clear |
| Tina M Binz, Elena Williner, Petra Strajhar, Patrick C Dolder, Matthias E Liechti, Markus R Baumgartner, Thomas Kraemer, Andrea E Steue. Chiral analysis of amphetamines in hair by liquid chromatography-tandem mass spectrometry: compliance-monitoring of attention deficit hyperactivity disorder (ADHD) patients under Elvanse® therapy and identification after controlled low-dose application. Drug testing and analysis. vol 10. issue 2. 2018-09-18. PMID:28440070. |
chiral analysis of amphetamines in hair by liquid chromatography-tandem mass spectrometry: compliance-monitoring of attention deficit hyperactivity disorder (adhd) patients under elvanse® therapy and identification after controlled low-dose application. |
2018-09-18 |
2023-08-13 |
human |
| Leonie Hennissen, Mireille J Bakker, Tobias Banaschewski, Sara Carucci, David Coghill, Marina Danckaerts, Ralf W Dittmann, Chris Hollis, Hanna Kovshoff, Suzanne McCarthy, Peter Nagy, Edmund Sonuga-Barke, Ian C K Wong, Alessandro Zuddas, Eric Rosenthal, Jan K Buitelaa. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS drugs. vol 31. issue 3. 2018-06-04. PMID:28236285. |
cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with adhd: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. |
2018-06-04 |
2023-08-13 |
Not clear |
| Neelam Shahani, Supriya Swarnkar, Vincenzo Giovinazzo, Jenny Morgenweck, Laura M Bohn, Catherina Scharager-Tapia, Bruce Pascal, Pablo Martinez-Acedo, Kshitij Khare, Srinivasa Subramania. RasGRP1 promotes amphetamine-induced motor behavior through a Rhes interaction network ("Rhesactome") in the striatum. Science signaling. vol 9. issue 454. 2017-11-20. PMID:27902448. |
in addition to stimulating the release of norepinephrine, amphetamines, which are used for narcolepsy and attention-deficit/hyperactivity disorder (adhd), trigger dopamine release in the striatum. |
2017-11-20 |
2023-08-13 |
mouse |